JP7828272B2 - Ｇｐｃ３特異的抗体およびその使用方法 - Google Patents

Ｇｐｃ３特異的抗体およびその使用方法

Info

Publication number
JP7828272B2
JP7828272B2 JP2022506163A JP2022506163A JP7828272B2 JP 7828272 B2 JP7828272 B2 JP 7828272B2 JP 2022506163 A JP2022506163 A JP 2022506163A JP 2022506163 A JP2022506163 A JP 2022506163A JP 7828272 B2 JP7828272 B2 JP 7828272B2
Authority
JP
Japan
Prior art keywords
antibody
fragment
amino acid
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544068A (ja
JP2022544068A5 (https=
Inventor
ラブカ，デイビッド
ドレイク，ペネロペ・エム
キム，ユン・チョル
バーフィールド，ロビン・エム
ボーゾン，マキシン
Original Assignee
アール．ピー．シェーラー テクノロジーズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アール．ピー．シェーラー テクノロジーズ エルエルシー filed Critical アール．ピー．シェーラー テクノロジーズ エルエルシー
Publication of JP2022544068A publication Critical patent/JP2022544068A/ja
Publication of JP2022544068A5 publication Critical patent/JP2022544068A5/ja
Application granted granted Critical
Publication of JP7828272B2 publication Critical patent/JP7828272B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022506163A 2019-08-01 2020-07-31 Ｇｐｃ３特異的抗体およびその使用方法 Active JP7828272B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881547P 2019-08-01 2019-08-01
US62/881,547 2019-08-01
PCT/US2020/044515 WO2021022166A1 (en) 2019-08-01 2020-07-31 Antibody specific for gpc3 and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022544068A JP2022544068A (ja) 2022-10-17
JP2022544068A5 JP2022544068A5 (https=) 2023-08-03
JP7828272B2 true JP7828272B2 (ja) 2026-03-11

Family

ID=74228511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506163A Active JP7828272B2 (ja) 2019-08-01 2020-07-31 Ｇｐｃ３特異的抗体およびその使用方法

Country Status (8)

Country Link
US (1) US12595314B2 (https=)
EP (1) EP4007604A4 (https=)
JP (1) JP7828272B2 (https=)
KR (1) KR20220083665A (https=)
CN (1) CN114340671A (https=)
AU (1) AU2020319874A1 (https=)
CA (1) CA3148807A1 (https=)
WO (1) WO2021022166A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118488970A (zh) * 2021-10-15 2024-08-13 乐普创一生物科技（上海）有限公司 抗磷脂酰肌醇蛋白聚糖3抗体
WO2025023650A1 (ko) * 2023-07-21 2025-01-30 한국생명공학연구원 신규한 항-gpc3 키메릭 항원 수용체 및 이를 발현하는 면역세포

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145469A1 (en) 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US20180346592A1 (en) 2015-10-29 2018-12-06 Mogam Institute For Biomedical Research Novel anti-glypican 3 antibody and pharmaceutical composition containing the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) * 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2009120611A2 (en) 2008-03-27 2009-10-01 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
US20170326249A1 (en) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145469A1 (en) 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US20180346592A1 (en) 2015-10-29 2018-12-06 Mogam Institute For Biomedical Research Novel anti-glypican 3 antibody and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
JP2022544068A (ja) 2022-10-17
WO2021022166A1 (en) 2021-02-04
CA3148807A1 (en) 2021-02-04
US12595314B2 (en) 2026-04-07
AU2020319874A1 (en) 2022-03-17
KR20220083665A (ko) 2022-06-20
US20220251237A1 (en) 2022-08-11
CN114340671A (zh) 2022-04-12
EP4007604A1 (en) 2022-06-08
EP4007604A4 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
US20220220198A1 (en) Antibody specific for cd22 and methods of use thereof
US20250084182A1 (en) Antibody specific for mucin-1 and methods of use thereof
JP7828272B2 (ja) Ｇｐｃ３特異的抗体およびその使用方法
US20260008852A1 (en) Anti-B7-H3 Antibody and Methods of Use Thereof
US12583930B2 (en) Human glucose-dependent insulinotropic polypeptide receptor (GIPR) antibodies and methods of use thereof to inhibit GIP receptor and signaling
EP4192883A1 (en) Anti-tigit antibody and methods of use thereof
AU2020299600A1 (en) Anti-CD38 antibody and methods of use thereof
WO2012106192A1 (en) Antibody specific for sulfatase-2 and methods of use thereof
EA052100B1 (ru) Антитело, специфичное в отношении муцина-1, и способы его применения
HK40010434A (en) Antibody specific for cd22 and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260227

R150 Certificate of patent or registration of utility model

Ref document number: 7828272

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150